Loading...
•
Sep 30, 2024
Nuvectis Pharma Q3 2024 Earnings Report
Reported financial results for the third quarter of 2024 and provided an update on recent business progress.
Key Takeaways
Nuvectis Pharma reported a net loss of $4.2 million for the third quarter of 2024. The company's cash, cash equivalents, and short-term investments were $17.2 million as of September 30, 2024. The company is continuing to advance the development programs of NXP800 and NXP900.
Advanced the development programs of NXP800 and NXP900.
Anticipate the upcoming clinical data update from the Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer this month for NXP800.
Obtained a second Orphan Drug Designation for NXP800 from the FDA, for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
Cleared 4 cohorts in the dose escalation Phase 1 study for NXP900 with no reports of dose limiting toxicities, and the dose escalation continues.
Nuvectis Pharma
Nuvectis Pharma
Forward Guidance
Nuvectis Pharma believes that its current cash position will allow it to meet important milestones for both clinical programs and provide working capital well into 2026.